anti vegfc monoclonal antibody vgx 100

Drug Overview

The anti-VEGF-C monoclonal antibody VGX-100 is an investigational medication designed to fight cancer by attacking the tumor’s supply lines. Because it is engineered to find and block specific proteins that help tumors grow and spread, this medication is a prime example of a Targeted Therapy.

• Generic Name: anti-VEGF-C monoclonal antibody VGX-100 (VGX-100)
• US Brand Names: None (Investigational drug)
• Drug Class: Monoclonal Antibody / Angiogenesis and Lymphangiogenesis Inhibitor (Targeted Therapy)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Not FDA Approved. This drug is currently strictly for use in clinical research trials and is not available to the general public.
  
  Find expert details on the anti vegfc monoclonal antibody vgx 100. Our leading medical hospital provides advanced clinical treatments for you.

What Is It and How Does It Work? (Mechanism of Action)

To understand how VGX-100 works, we need to look at how cancer grows and spreads. Tumors need oxygen and nutrients to survive. To get these, they release a special protein called Vascular Endothelial Growth Factor C (VEGF-C). This protein sends a signal telling the body to build new blood vessels (angiogenesis) and new lymphatic vessels (lymphangiogenesis) directly into the tumor. Cancer cells also use these new lymphatic vessels as a “highway” to spread to other parts of the body (metastasis).

VGX-100 is a lab-made antibody designed to stop this process at the molecular level:

1. Hunting the Protein: Once in the bloodstream, VGX-100 seeks out and tightly binds directly to the VEGF-C proteins floating around the tumor.
2. Blocking the Signal: By locking onto VEGF-C, the drug prevents this protein from attaching to its normal “landing pads” (called VEGFR-2 and VEGFR-3 receptors) located on the walls of blood and lymphatic vessels.
3. Starving the Tumor: Because the receptors never receive the growth signal, the body stops building new blood and lymph vessels around the tumor.
4. Trapping the Cancer: Without new lymphatic vessels, the tumor loses its main escape route, making it much harder for the cancer cells to spread to nearby lymph nodes. At the same time, the lack of new blood vessels starves the tumor of the nutrients it needs to keep growing.

FDA-Approved Clinical Indications

Because VGX-100 is still an investigational drug in clinical trials, it does not currently have any official FDA-approved uses. It is being studied by researchers for the following conditions:

Investigational Oncological Uses

• Advanced Solid Tumors
• Glioblastoma (a type of aggressive brain cancer)
• Prostate Cancer
• Tumors with a high risk of spreading to the lymph nodes

Investigational Non-Oncological Uses

• None at this time. (Research is currently focused entirely on cancer and tumor-related vessel growth).

Dosage and Administration Protocols

Note: Because VGX-100 is an experimental drug, there is no standard dose for the public. The table below shows the general guidelines used during early-phase (Phase 1) clinical trials to test for safety.

Clinical Efficacy and Research Results

When looking at clinical studies from recent years (2020–2025), it is important to know that VGX-100 has primarily been evaluated in early Phase 1 trials. These early trials are designed to test if a drug is safe, rather than to gather large amounts of numerical data on survival rates.

Because it has not yet moved into massive Phase 3 trials, exact percentages for overall survival or tumor shrinkage are not available. However, the early research proved a very important medical concept: targeting the VEGF-C protein is a safe and possible way to restrict tumor vessel growth. General trial results showed that the drug was well-tolerated by patients with advanced solid tumors, and it successfully blocked the targeted proteins in the blood. Researchers are now using this knowledge to explore how blocking lymph vessel growth might be combined with other cancer treatments in the future.

Safety Profile and Side Effects

Like all medications that affect blood vessels, VGX-100 has specific side effects that doctors watch for very carefully.

Common Side Effects (>10%)

• High Blood Pressure (Hypertension): Narrowing of the blood vessels can cause blood pressure to rise.
• Fatigue: Feeling unusually tired or weak.
• Headache: Often related to changes in blood pressure.
• Mild Proteinuria: A small, usually harmless amount of protein leaking into the urine.

Serious Adverse Events

• Bleeding Issues: Because the drug stops new blood vessels from forming, it can interfere with healing and cause severe bleeding (hemorrhage) from the nose, stomach, or tumor sites.
• Poor Wound Healing: Cuts, surgical wounds, or injuries may heal very slowly or open up.

Black Box Warning

Since VGX-100 is not FDA-approved, it does not have a formal Black Box Warning. However, all drugs in the VEGF-inhibitor family carry serious warnings about severe bleeding, trouble healing wounds, and stomach/intestinal tears (perforations). Doctors treat VGX-100 with these same strict precautions.

Management Strategies

If a patient develops high blood pressure, the doctor will usually prescribe standard daily blood pressure pills. If a patient experiences severe bleeding or needs surgery, the VGX-100 infusions will be stopped immediately until the issue is resolved.

Research Areas

While VGX-100 is not a stem cell therapy, its ability to change the environment around a tumor makes it an exciting subject for Immunotherapy research. Tumors use blood and lymphatic vessels to create a protective barrier against the body’s immune system. Current research suggests that by using targeted therapies like VGX-100 to destroy these “tumor highways,” we might make it easier for immune cells (or immunotherapy drugs) to enter the tumor and destroy the cancer cells from the inside out.

Patient Management and Practical Recommendations

Patients enrolled in clinical trials for VGX-100 are monitored closely by their oncology team to ensure safety.

Pre-Treatment Tests

• Blood Pressure Check: Must be strictly controlled before the first drip.
• Urine Test (Urinalysis): To check if the kidneys are leaking protein.
• Complete Blood Count (CBC) and Organ Panels: To make sure the liver, kidneys, and blood clotting systems are healthy.

Precautions During Treatment

Patients who have recently had major surgery, have stomach ulcers, or are taking strong blood thinners are generally not allowed to take this medication because of the high risk of bleeding and poor healing.

Do’s and Don’ts

• DO check your blood pressure at home every day and keep a record for your doctor.
• DO tell your doctor immediately if you see blood in your urine, have dark/tarry stools, or cough up blood.
• DO use a soft toothbrush and an electric razor to prevent accidental cuts.
• DON’T schedule any surgeries, even minor dental work, without telling your cancer doctor first.
• DON’T take over-the-counter pain medicines like ibuprofen, aspirin, or naproxen without asking your doctor, as they can increase your risk of bleeding.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. The anti-VEGF-C monoclonal antibody VGX-100 is an investigational compound and is not approved by the FDA, EMA, or other global regulatory agencies for the treatment of any disease. Patients should always consult with a qualified, licensed healthcare professional or oncologist regarding treatment options, clinical trials, and medication safety. Do not disregard professional medical advice or delay seeking it because of information provided on this website.